Nurix Therapeutics (NRIX) Non-Current Assets (2019 - 2026)

Nurix Therapeutics (NRIX) has 8 years of Non-Current Assets data on file, last reported at $81.7 million in Q1 2026.

• Non-Current Assets for Q1 2026 came in at $81.7 million, up 59.21% year-over-year; the trailing twelve-month figure through Feb 2026 was $321.1 million (up 46.2% YoY), and the FY2025 annual result was $81.3 million, up 62.78% from the prior year.
• Non-Current Assets grew to $81.7 million in Q1 2026 per NRIX's latest filing, from $81.3 million in the prior quarter.
• Over five years, Non-Current Assets peaked at $157.2 million in Q1 2022 and troughed at $40.2 million in Q3 2023.
• A 5-year average of $76.0 million and a median of $76.2 million in 2025 frame the typical range for Non-Current Assets.
• The sharpest annual moves came in 2022 and 2023: Non-Current Assets surged 83.06% in 2022, then slumped 61.47% in 2023.
• A 5-year view of Non-Current Assets shows it stood at $98.3 million in 2022, then sank by 38.87% to $60.1 million in 2023, then fell by 16.87% to $50.0 million in 2024, then soared by 62.78% to $81.3 million in 2025, then advanced by 0.52% to $81.7 million in 2026.
• Business Quant data shows NRIX's Non-Current Assets at $81.7 million in Q1 2026, $81.3 million in Q4 2025, and $81.9 million in Q3 2025.